CANDEL THERAPEUTICS INC. - COMMON STOCK

Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors

08 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference

05 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

19 May 2023 08:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

11 May 2023 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Upcoming Presentations at ASGCT and ASCO

02 May 2023 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer

17 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights

30 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics to Participate in Guggenheim Healthcare Talks 2023 Oncology Day

01 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics to Participate in Upcoming B. Riley Oncology Conference

12 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics R&D Day Presentations Spotlight its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer

06 Dec 2022 15:26:35 By Nasdaq GlobeNewswire

Candel Therapeutics to Host Virtual R&D Day on December 6, 2022

29 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting

18 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma

11 Nov 2022 11:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

10 Nov 2022 07:00:03 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Upcoming Clinical Data Presentations at SITC and SNO

07 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Candel Therapeutics Upcoming Investor Conference Participation for November

01 Nov 2022 07:00:03 By Nasdaq GlobeNewswire

Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models

26 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for CAN-2409 in Glioma

15 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Two Executive Leadership Appointments

07 Sep 2022 07:00:02 By Nasdaq GlobeNewswire

Candel Therapeutics Upcoming Investor Conference Participation

06 Sep 2022 07:00:02 By Nasdaq GlobeNewswire